Based on the Lonza Group Ltd stock forecast from 0 analysts, the average analyst target price for Lonza Group Ltd is not available over the next 12 months. Lonza Group Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Lonza Group Ltd is Neutral, which is based on 6 positive signals and 7 negative signals. At the last closing, Lonza Group Ltd’s stock price was USD 649.96. Lonza Group Ltd’s stock price has changed by +11.45% over the past week, +10.70% over the past month and +53.75% over the last year.
No recent analyst target price found for Lonza Group Ltd
No recent average analyst rating found for Lonza Group Ltd
Company Overview Lonza Group Ltd
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland. Read Less
Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small M...Read More
Frequently Asked Questions About Lonza Group Ltd (LZAGF) Stock
Stock Target Advisor's fundamental analysis for Lonza Group Ltd's stock is Neutral.
LZAGF stock's dividend yield is 0.71%.
Our analysis grades LZAGF stock's dividend yield at F. This means that LZAGF stock's dividend yield is above 11% of the stocks in the Diagnostics & Research sector in the OTC exchange.
Based on this LZAGF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on LZAGF's stock to indicate what its average analyst target is.
LZAGF stock's Price/Earning ratio is 71.42.
Our analysis grades LZAGF stock's Price / Earning ratio at F. This means that LZAGF stock's Price/Earning ratio is above 89% of the stocks in the Diagnostics & Research sector in the OTC exchange.
Based on this LZAGF may be a overvalued for its sector.
The last closing price of LZAGF's stock was USD 649.96.
The most recent market capitalization for LZAGF is USD 44.91B.
Unfortunately we do not have enough analyst data on LZAGF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Lonza Group Ltd's stock.
As per our most recent records Lonza Group Ltd has 17,834 Employees.
Lonza Group Ltd's registered address is Muenchensteinerstrasse 38, Basel, Switzerland, 4002.
You can get more information about it from Lonza Group Ltd's website at https://www.lonza.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Dividend Growth
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Lonza Group Ltd (LZAGF) Stock
Stock Target Advisor's fundamental analysis for Lonza Group Ltd's stock is Neutral.
LZAGF stock's dividend yield is 0.71%.
Our analysis grades LZAGF stock's dividend yield at F. This means that LZAGF stock's dividend yield is above 11% of the stocks in the Diagnostics & Research sector in the OTC exchange.
Based on this LZAGF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on LZAGF's stock to indicate what its average analyst target is.
LZAGF stock's Price/Earning ratio is 71.42.
Our analysis grades LZAGF stock's Price / Earning ratio at F. This means that LZAGF stock's Price/Earning ratio is above 89% of the stocks in the Diagnostics & Research sector in the OTC exchange.
Based on this LZAGF may be a overvalued for its sector.
The last closing price of LZAGF's stock was USD 649.96.
The most recent market capitalization for LZAGF is USD 44.91B.
Unfortunately we do not have enough analyst data on LZAGF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Lonza Group Ltd's stock.
As per our most recent records Lonza Group Ltd has 17,834 Employees.
Lonza Group Ltd's registered address is Muenchensteinerstrasse 38, Basel, Switzerland, 4002.
You can get more information about it from Lonza Group Ltd's website at https://www.lonza.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LZAGF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
